Two phase 3 trials and a meta-analysis involving patients with type 1 diabetes have demonstrated lower rates of nocturnal hypoglycaemia with insulin degludec compared to insulin glargine U100 [11–13]. The gene discussed is INS; the disease is type 1 diabetes mellitus.